Clinical trials: FLU
Influenza, Pneumonia
Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada
Excellent immune responses following 1 or 2 doses of the GSK monovalent AS03-adjuvanted pandemic H1N1 (pH1N1) vaccines (e.g., Arepanrix®) have been documented in several trials.
- Trial name
- NCT01622491
- Where
- Canada
- Volunteers
- 1,860 people
- Sponsor
- International Centre for Infectious Diseases, Canada
Influenza
Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT
Influenza is an important cause of medical visits and worker absenteeism among healthy adults. Studies of healthcare providers vaccination programmes have reported a positive effect in lowering rates of influenza like illness and…
- Trial name
- NCT02589574
- Testing
- electronic text message
- Where
- China
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Healthy Free-living Elderly
Effect of the Consumption of a Fermented Dairy Drink on the Immune Function
The purpose of this study is to determine whether the regular consumption of the active product enhances the immune function, in comparison to the control product.
- Trial name
- NCT01521182
- Testing
- 1-Fermented Dairy Product (test), 2-Milk-based non-fermented dairy product (control)
- Where
- Belgium
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Influenza
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age.
- Trial name
- NCT01934127
- Testing
- Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A
- Where
- 9 sites in United States, Canada
- Volunteers
- 427 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine
Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults
This is a double-blind, placebo controlled, safety and immunogenicity study of GelVac™ nasal powder H5N1 influenza vaccine. Healthy male and female subjects between 18 and 49 years of age who are eligible for study participation…
- Trial name
- NCT01258062
- Testing
- GelVac™ nasal powder H5N1 influenza vaccine.
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Flu
Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis
It appears that the heavyness of flu pathology, the diagnosis limits and the validity of it was well studied in the last years.However, the economical impact and the organisation benefit in emergency service is not yet evaluated…
- Trial name
- NCT03293979
- Testing
- Test A i Flu A&B implemented in emergency service
- Where
- France
- Volunteers
- 301 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Influenza
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
- Trial name
- NCT04603989
- Testing
- HNC042 for Injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Influenza
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
Primary Objective: To describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine Fluzone®, given in the two-dose schedule (described in the package insert for vaccine-naïve young…
- Trial name
- NCT00858468
- Testing
- Influenza virus vaccine (2004-2005 Formulation)
- Where
- 8 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01303510
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations
This is a Phase II open-label study in approximately 200, and up to 240, healthy males and non-pregnant females, aged 18 years and older.
- Trial name
- NCT01746082
- Testing
- Influenza A/H3N2 variant Vaccine
- Where
- 4 sites in United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pregnancy, Influenza
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on vaccine exposures, pregnancy outcomes, and…
- Trial name
- NCT01945424
- Testing
- Quadrivalent Influenza Vaccine (QIV)
- Where
- 5 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Orthomyxoviridae Infections
Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects
Primary Objective: To describe the immunogenicity of an injection of the investigational inactivated, split-virion influenza vaccine 21 days after vaccination in 18 to 60 years old renal transplant subjects identified as…
- Trial name
- NCT00606359
- Testing
- Inactivated, split-virion influenza virus
- Where
- France
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Viral Infections, RSV Infection
Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room
Molecular techniques for respiratory virus detection have already shown benefits in terms of sensitivity gained in comparison to conventional techniques.
- Trial name
- NCT05105191
- Testing
- Roche Cobas® Liat Influenza A/B & RSV assay
- Where
- 4 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Erasme University Hospital
Respiratory Viral Infection
Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza
The goal of this phase III study is to learn if ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
- Trial name
- ZX-7101A-214 (NCT07095257)
- Testing
- ZX-7101A for oral suspension, Oseltamivir phosphate for oral suspension
- Where
- 2 sites in China
- Volunteers
- 169 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus…
- Trial name
- NCT00970177
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pulmonary Sarcoidosis
Antibody Response to Influenza Vaccine in Patients With Sarcoidosis
The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.
- Trial name
- IVS (NCT00828828)
- Testing
- Influenza Vaccine
- Where
- Iran
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Influenza A Virus Infection, Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups…
- Conditions
- Influenza A Virus Infection, Influenza A, Influenza Epidemic, Influenza H5N1
- Trial name
- NCT03651544
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Complement Deficiency, Antibody Deficiency
Systematic Search for Primary Immunodeficiency in Adults With Infections
Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections …
- Conditions
- Complement Deficiency, Antibody Deficiency, Chronic Sinus Infection, Meningitis, Bacterial
- Trial name
- SPIDAC (NCT02972281)
- Testing
- Immunological diagnosis tests
- Where
- 19 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Lille
Influenza Virus
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.
- Trial name
- NCT01561807
- Testing
- VX-787
- Where
- United Kingdom
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.